BR112014031421A2 - composições para tratamento de câncer e métodos para produção das mesmas - Google Patents
composições para tratamento de câncer e métodos para produção das mesmasInfo
- Publication number
- BR112014031421A2 BR112014031421A2 BR112014031421A BR112014031421A BR112014031421A2 BR 112014031421 A2 BR112014031421 A2 BR 112014031421A2 BR 112014031421 A BR112014031421 A BR 112014031421A BR 112014031421 A BR112014031421 A BR 112014031421A BR 112014031421 A2 BR112014031421 A2 BR 112014031421A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- producing
- cancer treatment
- treatment compositions
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo da patente de invenção para: composições para tratamento de câncer e métodos para produção das mesmas são aqui descritas composições e métodos relacionados a agentes quimioterapêuticos conjugados e o tratamento de câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261689950P | 2012-06-15 | 2012-06-15 | |
US201261797484P | 2012-12-07 | 2012-12-07 | |
PCT/US2013/045893 WO2013188763A1 (en) | 2012-06-15 | 2013-06-14 | Compositions for treating cancer and methods for making the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014031421A2 true BR112014031421A2 (pt) | 2017-06-27 |
Family
ID=49758748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014031421A BR112014031421A2 (pt) | 2012-06-15 | 2013-06-14 | composições para tratamento de câncer e métodos para produção das mesmas |
Country Status (7)
Country | Link |
---|---|
US (2) | US9789193B2 (pt) |
EP (1) | EP2861256B1 (pt) |
JP (2) | JP6427097B2 (pt) |
CN (1) | CN104582732A (pt) |
AU (2) | AU2013274101B2 (pt) |
BR (1) | BR112014031421A2 (pt) |
WO (1) | WO2013188763A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
PE20141303A1 (es) | 2011-01-10 | 2014-10-01 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
WO2013009701A2 (en) | 2011-07-08 | 2013-01-17 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US10017531B2 (en) * | 2013-06-14 | 2018-07-10 | Invictus Oncology Pvt. Ltd. | Lipid-based platinum-N-heterocyclic carbene compounds and nanoparticles |
JP6461973B2 (ja) * | 2013-12-20 | 2019-01-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 2以上の疎水性ドメインおよびpeg部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用 |
JP6302560B2 (ja) | 2013-12-20 | 2018-03-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリエチレングリコール部分を含む化合物を用いて支持体に細胞を固定化する方法 |
CA2930505C (en) * | 2013-12-20 | 2019-06-18 | F. Hoffman-La Roche Ag | Compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising peg moieties, useful for binding cells |
US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
RU2016140160A (ru) * | 2014-04-03 | 2018-05-07 | Инвиктус Онколоджи Пвт. Лтд. | Супрамолекулярные комбинаторные лекарственные средства |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
EP3206987B1 (en) | 2014-10-14 | 2020-07-01 | The University of Chicago | Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof |
US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
US10736845B2 (en) | 2015-03-03 | 2020-08-11 | Cureport Inc. | Dual loaded liposomal pharmaceutical formulations |
WO2016182988A1 (en) * | 2015-05-08 | 2016-11-17 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of glioma |
CN105044343B (zh) * | 2015-08-14 | 2017-03-08 | 山东省肿瘤防治研究院 | 一种食管鳞状细胞癌诊断模型的构建方法、所得诊断模型及模型的使用方法 |
US10736968B2 (en) | 2016-02-11 | 2020-08-11 | Invictus Oncology Pvt. Ltd. | Cellular signalling inhibitors, their formulations and methods thereof |
US11517539B2 (en) | 2016-02-15 | 2022-12-06 | University Of Georgia Research Foundation, Inc. | IPA-3-loaded liposomes and methods of use thereof |
EP3439666A4 (en) | 2016-05-20 | 2019-12-11 | The University of Chicago | NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ANY COMBINATION THEREOF |
MX2018016227A (es) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
WO2018146641A1 (en) * | 2017-02-11 | 2018-08-16 | Invictus Oncology Pvt. Ltd. | Novel inhibitors of cellular signalling |
CN111194232B (zh) | 2017-08-02 | 2023-01-31 | 芝加哥大学 | 纳米级金属有机层和金属有机纳米片 |
CA3085759A1 (en) * | 2017-12-14 | 2019-06-20 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
CN108434457B (zh) * | 2018-04-20 | 2021-06-18 | 长沙创新药物工业技术研究院有限公司 | 一种阿霉素聚乙二醇埃博霉素b偶联物及其制备方法 |
US20220000777A1 (en) * | 2018-11-02 | 2022-01-06 | Tesorx Pharma, Llc | Liposomal enhanced intra-peritoneal chemotherapy |
US11826430B2 (en) | 2019-05-14 | 2023-11-28 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN114401736A (zh) * | 2019-08-13 | 2022-04-26 | 佩蒂诺沃生物制药公司 | 用于治疗伴随癌症治疗发生的化学疗法诱导的周围神经病变的palm |
EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2021164789A1 (zh) * | 2020-02-21 | 2021-08-26 | 南京明德新药研发有限公司 | 一种吡唑并嘧啶类化合物的晶型及其应用 |
WO2021226148A1 (en) * | 2020-05-04 | 2021-11-11 | Drugcendr Australia Pty Ltd. | Methods for treating pancreatic cancer and other solid tumors |
JP2023552809A (ja) * | 2020-12-10 | 2023-12-19 | チルドレンズ ホスピタル メディカル センター | 増強されたナノ粒子送達システム |
CA3205397A1 (en) * | 2020-12-24 | 2022-06-30 | EnhancedBio Inc. | Composition for preventing or treating cancer, containing lipid nanoparticles |
US11834458B2 (en) | 2021-03-23 | 2023-12-05 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2023068958A1 (ru) * | 2021-10-19 | 2023-04-27 | Борис Славинович ФАРБЕР | Супрамолекулярные системы на основе динамических самоорганизующихся наноструктур с противовирусными свойствами |
CN114288422B (zh) * | 2022-01-21 | 2023-04-28 | 陕西科技大学 | 一种化学靶向降解目标蛋白的脂质体及其制备方法 |
WO2023230616A2 (en) * | 2022-05-26 | 2023-11-30 | Purdue Research Foundation | Combination of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of use |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
JPH089548B2 (ja) * | 1986-03-14 | 1996-01-31 | 藤沢薬品工業株式会社 | プロドラツグ化合物、その製造法およびそれを含有する持続性製剤 |
ATE63124T1 (de) | 1986-03-14 | 1991-05-15 | Fujisawa Pharmaceutical Co | Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung. |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
IL95436A (en) | 1989-08-23 | 1996-07-23 | Centre Nat Rech Scient | Process for preparing the history of phenylisosarine |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5015744A (en) | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
FR2658510B1 (fr) | 1990-02-21 | 1992-04-30 | Rhone Poulenc Sante | Nouveau derive de la beta-phenylisoserine, sa preparation et son emploi. |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
FR2678930B1 (fr) | 1991-07-10 | 1995-01-13 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii. |
FR2680506B1 (fr) | 1991-08-19 | 1994-09-02 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la beta-phenylisoserine et leur utilisation. |
AU3140093A (en) | 1991-11-22 | 1993-06-15 | University Of Mississippi, The | Synthesis and optical resolution of the taxol side chain and related compounds |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
FR2687150B1 (fr) | 1992-02-07 | 1995-04-28 | Rhone Poulenc Rorer Sa | Procede de preparation de derives du taxane. |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
TW225528B (pt) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EP0833613A1 (en) | 1995-05-26 | 1998-04-08 | Somatix Therapy Corporation | Delivery vehicles comprising stable lipid/nucleic acid complexes |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US6140332A (en) | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
ATE308527T1 (de) | 1996-06-24 | 2005-11-15 | Pfizer | Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten |
NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
ATE247724T1 (de) | 1996-09-06 | 2003-09-15 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
AU5620299A (en) | 1998-08-11 | 2000-03-06 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
US6218367B1 (en) | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
EP1135470A2 (en) | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
EP1383492A4 (en) * | 2001-03-23 | 2008-12-24 | Napro Biotherapeutics Inc | MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
CA2730540A1 (en) * | 2004-05-13 | 2005-12-01 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
WO2005118612A1 (en) * | 2004-06-04 | 2005-12-15 | Sonus Pharmaceuticals, Inc. | Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs |
CN1743337B (zh) * | 2004-09-03 | 2012-06-13 | 上海复旦张江生物医药股份有限公司 | 一种紫杉醇衍生物及其药物组合物 |
JP2007099750A (ja) * | 2005-02-25 | 2007-04-19 | Hokkaido Univ | 腫瘍組織で選択的に分解性を示す血中滞留性素子 |
EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | ELEMENT RETAINED IN BLOOD SHOWING SELECTIVE DEGRADABILITY IN TUMOR TISSUE |
US9107824B2 (en) * | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
CN101616677B (zh) | 2006-10-03 | 2015-07-22 | 阿尔尼拉姆医药品有限公司 | 含脂质的制品 |
AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
SI2131821T1 (sl) | 2007-03-07 | 2018-11-30 | Abraxis Bioscience, Llc | Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku |
US9207990B2 (en) | 2007-09-28 | 2015-12-08 | Hewlett-Packard Development Company, L.P. | Method and system for migrating critical resources within computer systems |
US8486924B2 (en) * | 2007-11-28 | 2013-07-16 | Celator Pharmaceuticals, Inc. | Taxane delivery system |
AU2008333811B2 (en) | 2007-12-04 | 2014-05-01 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
CA2711236A1 (en) | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
EP2421536B1 (en) * | 2009-04-20 | 2015-08-26 | Gilead Calistoga LLC | Methods of treatment for solid tumors |
WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2013
- 2013-06-14 JP JP2015517453A patent/JP6427097B2/ja not_active Expired - Fee Related
- 2013-06-14 AU AU2013274101A patent/AU2013274101B2/en not_active Ceased
- 2013-06-14 EP EP13805073.7A patent/EP2861256B1/en active Active
- 2013-06-14 US US14/406,938 patent/US9789193B2/en active Active
- 2013-06-14 BR BR112014031421A patent/BR112014031421A2/pt not_active IP Right Cessation
- 2013-06-14 CN CN201380043472.9A patent/CN104582732A/zh active Pending
- 2013-06-14 WO PCT/US2013/045893 patent/WO2013188763A1/en active Application Filing
-
2017
- 2017-10-02 US US15/722,831 patent/US10300143B2/en active Active
- 2017-11-24 AU AU2017265136A patent/AU2017265136A1/en not_active Abandoned
-
2018
- 2018-06-21 JP JP2018117597A patent/JP2018188443A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018188443A (ja) | 2018-11-29 |
WO2013188763A9 (en) | 2014-01-23 |
EP2861256A4 (en) | 2016-06-01 |
AU2013274101A1 (en) | 2015-01-29 |
AU2017265136A1 (en) | 2018-01-04 |
US10300143B2 (en) | 2019-05-28 |
CN104582732A (zh) | 2015-04-29 |
JP6427097B2 (ja) | 2018-11-21 |
EP2861256B1 (en) | 2019-10-23 |
US20150174263A1 (en) | 2015-06-25 |
US9789193B2 (en) | 2017-10-17 |
AU2013274101B2 (en) | 2017-09-07 |
WO2013188763A1 (en) | 2013-12-19 |
EP2861256A1 (en) | 2015-04-22 |
US20180125987A1 (en) | 2018-05-10 |
JP2015527301A (ja) | 2015-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014031421A2 (pt) | composições para tratamento de câncer e métodos para produção das mesmas | |
CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
BR112017023269A2 (pt) | métodos para tratamento de câncer | |
PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
EA201590987A1 (ru) | Соединения и способы их применения | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
EA201400178A1 (ru) | Лечение рака молочной железы | |
WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
UY36075A (es) | Derivados de tubulisina | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
BR112015030203A2 (pt) | moléculas pequenas inibidores da fibrose | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
EA201590997A1 (ru) | Соединения и способы их применения | |
GB201209613D0 (en) | New compounds | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
BR112014008819A2 (pt) | métodos para o tratamento de síndrome de vazamento vascular e câncer | |
EA201490944A1 (ru) | Двойной ингибитор met и vegf для лечения рака | |
BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2624 DE 20/04/2021. |